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Abstract
The prevalence of asthma is about 9,7 % in women and 5,5 % in men.
Asthma can deteriorate during the perimenstrual period, a phenomenon known as perimenstrual asthma (PMA),
which represents a unique, highly symptomatic asthma phenotype. It is distinguished from traditional allergic
asthma by aspirin sensitivity, less atopy, and lower lung capacity.
PMA incidence is reported to vary between 19 and 40 % of asthmatic women. The presence of PMA has been
related to increases in asthma-related emergency department visits, hospitalizations and emergency treatment
including intubations.
It is hypothesized that hormonal status may influence asthma in women, focusing on the role of sex hormones,
and specifically on the impact of estrogens’ fluctuations at ovulation and before periods.
This paper will focus on the pathophysiology of hormone triggered cycle related inflammatory/allergic events
and their relation with asthma. We reviewed the scientific literature on Pubmed database for studies on PMA. Key
word were PMA, mastcells, estrogens, inflammation, oral contraception, hormonal replacement therapy (HRT), and
hormone free interval (HFI).
Special attention will be devoted to the possibility of reducing the perimenstrual worsening of asthma and
associated symptoms by reducing estrogens fluctuations, with appropriate hormonal contraception and reduced
HFI. This novel therapeutical approach will be finally discussed.
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Background
Asthma is one of the most common chronic respira-
tory diseases. According to the Centers for Disease
Control and Prevention (CDC) and to 2000 Behavioral
Risk Factor Surveillance System, the prevalence of
asthma ranges from 9.1 to 9,7 % in adult women and
5.1 to 5,5 % in men, i.e. women present almost twice
the risk men have [1, 2]. The increased vulnerability to
inflammatory and autoimmune disease women experi-
ence after puberty is considered secondary to the dif-
ferent effect sex hormones have on the inflammatory
defense system, and specifically on mast-cells (MC) [3,
4] and eosinophils cells. Fluctuations of estrogens trig-
ger the mast-cell degranulation, whilst testosterone
and other androgens are credited to have a stabilizing
effect. Perimenstrual fluctuations of sex hormones in
women are considered responsible for the specific
worsening of many different perimenstrual symptoms
and of specific inflammatory [5], autoimmune [6, 7]
and pain related conditions, such as headache and pel-
vic pain [8–11].
The focus of this paper will be twofold: 1. To analyze
the pathophysiology of menstrual cycle related events
(ovulations and periods) and their relation with ovula-
tory and, with specific focus, PMA; 2. To discuss
preventive strategies aiming at reducing the cycle –
related inflammatory/allergic worsening of asthma and
associated symptoms by reducing estrogens fluctua-
tions, with appropriate hormonal contraception and
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Asthma in women’s lifespan: windows of vulnerability
➢ Puberty: asthma is more common and severe in
women during and after puberty. Prevalence is
higher in women with early menarche [12]
➢ Ovulation: asthma exacerbations begin more often
during the preovulatory (28 %) period in women
with this chronic condition. Ovulation associated
sex hormones’ fluctuations may trigger asthmatic
crisis in vulnerable women [12–15].
➢ Menstruation: asthma can deteriorate during the
perimenstrual period, a phenomenon known as
perimenstrual asthma (PMA) which is usually much
more severe and troublesome than the periovulatory
worsening [16].
➢ Pregnancy: the clinical course of asthma during
pregnancy is variable: it may worsen in about one-
third of pregnant women, and may improve in about
one-quarter [17–20]. It appears that mild asthma is
likely to improve, whereas more severe forms of the
disease frequently worsen [17–20]. Asthma generally
improves during the last 4 weeks of gestation, and
attacks are very infrequent during labor and delivery
[17, 20]
➢ Puerperium: changes in the asthmatic state during
pregnancy generally last up to 3 months after
delivery [17, 20].
➢ Menopause: postmenopausal women present a
significantly lower risk of developing asthma than
premenopausal women of similar age [17, 21]
➢ HRT: results in the effect of HRT on asthma are
controversial. In one study, ever using HRT was
associated with increased risk of hospital
admission for asthma. This risk was highest with
the longest duration of HRT use. The risk was
significantly increased for all types of HRT
regimens [22]
In other studies neither the discontinuation nor
reinitiation of HRT in the postmenopausal period has
any effect on airway obstruction in asthmatic women
[21, 23].
Definition of PMA
A clear definition of PMA does not exist in the lit-
erature. Murpyh et al. investigated the following types
of PMA definitions: self-reported PMA, increased
symptoms, increased medication use, decreased peak
flow or a combination of changes in symptoms, medi-
cation and peak flow. The variability of the definition
of PMA affects the recollection of the data in the dif-
ferent studies and affects the prevalence in different
populations [24].
Generally, the deterioration of asthma during the luteal
phase and/or during the first days of menstruation, is
characterized by deterioration of lung function tests [25].
PMA represents a unique, highly symptomatic, and
exacerbation-prone asthma phenotype associated with
aspirin sensitivity, less atopy (less IgE level), and lower
forced vital capacity, that distinguish it from traditional
allergic asthma [26].
Prevalence of PMA
PMA incidence is reported to be as high as 40 % of asth-
matic women [27].
In population based studies, rates of admissions to hos-
pital for asthma are similar by sex in the early teenage
years [13, 28, 29] but three times higher in women than in
men aged 20–50 years. After menopause the incidence of
asthma falls and equalizes again with men [13, 28, 29].
The presence of PMA has been related to increases in
asthma-related Emergency Department (ED) visits, hos-
pitalizations, intensive care unit (ICU) admissions, in-
tubations, and near-fatal and fatal events [13, 26].
ED visits occur more commonly among women in
the preovulatory (28 %) and perimenstrual (27 %) phases
(p = 0.004) [13].
These findings, together with the growing body of evi-
dence for sex differences in asthma [12, 13], support the
hypothesis that hormonal status may influence asthma in
women, focusing on the role of sex hormones, and specif-
ically on the impact of estrogens’ fluctuations at ovulation
and before periods [13].
Why do ovulation and menstruation trigger asthma attacks?
New data suggest that specific pathophysiologic mecha-
nisms could be responsible for PMA attacks. An updated
physiology of the cycle related events will be briefly
reviewed here, to set the scenario which leads to PMA. It
focuses on the inflammatory nature of the menstrual
process, currently understood as the “genital sign of sys-
temic endocrine and inflammatory events” [3, 4].
➢ The updated physiology of estrogen’ fluctuations at
ovulation and menstruation
The physiology of the menstrual cycle is characterized
by fluctuating levels of luteinizing hormone (LH),
follicle-stimulating hormone (FSH), oestradiol, proges-
terone and testosterone. The perimenstrual phase is
characterized by a decline in progesterone and oestradiol
levels [30], which triggers MC degranulation at the basal
layer of the endometrium. This induces a local (with
endometrial tissue breakdown and menstruation) and a
systemic inflammation (with MC and eosinophil de-
granulation and consequent increase in inflammatory
markers in tissues where hyperactive MC are already
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present, such as the lung/bronchial tissues of an asth-
matic woman) [3].
➢ Effect of estrogens on immune cells
Sex hormones are effective modulators of immune
and inflammatory responses [31]. Estrogens signifi-
cantly influence the incidence and/or the course of
several autoimmune diseases, as well as bacterial and
parasitic infectious processes [31–34]. They exert their
actions through the estrogen receptor (ER)-alpha and
-beta [31, 34–36], which are expressed by several im-
mune cells [37].
– Eosinophils : Chronic administration of E2 to
ovariectomized mice prevents eosinophilia in sterile
peritonitis induced by thyoclicolate challenge (with a
sixfold decrease in circulating eosinophils as
compared with untreated ovariectomized mice) [31].
– MC: MC are considered to be the chief protagonists
in the clinical scenario of inflammation and pain
[3, 4, 38–40]. MC are present in the endometrium
and myometrium and are predominantly localized
to the basal layer [41]. MC are upregulated in
response to a wide range of stimuli, including
neurogenic factors, fluctuating oestrogen levels
and menstrual blood in the tissue [9]. Once
activated, MC degranulate and release a range of
inflammatory mediators which perpetuate the
immune response [9]. Sex hormones regulate MC
functionality and distribution in several tissues
[42–47], both in physiological and pathological
conditions. In this regard, a relationship between
female sex hormones, MC and development of
asthma and allergy has been suggested [46–49].
Furthermore, the presence of sex steroid receptors
on MC indicates that sex hormones may exert
their biological effects by binding to these
receptors [49].
Asthma and respiratory atopy
Asthma, allergies and other manifestations of atopy have
also been shown to fluctuate throughout the menstrual
cycle [50].
The female immune response changes throughout the
menstrual cycle. Many studies support this theory:
➢ One study examining skin prick testing in women
with aero-allergens reported significantly increased
wheel-and- flare responses on days 12–16 of the
menstrual cycle which correspond to ovulatory peak
estrogen levels [51].
➢ The menstrual phase has also been shown to
influence nasal reactivity, as the period of peak
estrogen is correlated with the nasal mucosa
becoming hyperreactive to histamine [52].
➢ Bronchial hyperreactivity is more likely in the
perimenstrual period than at other points in the
cycle; PMA seems to be closely linked to total IgE
levels but not to specific allergens [53].
➢ Atopic asthma, a specific asthma phenotype, is often
associated to an irregular menstrual cycle [54, 55]
Asthma and combined contraceptive pill
Studies have demonstrated a role for both exogenous
estrogen and progesterone in the management of PMA
[25, 56–58]. In a prospective study on postpubertal
women with asthma, the 106 women using oral contra-
ception (OC) had reduced asthma symptoms, improved
pulmonary function, and improved asthma control com-
pared with those not using OC [57].
A study from Tan et al. compared airway reactivity to
adenosine monophosphate (AMP) in female asthmatics
with natural menstrual cycles and those taking the OC
(with 21 days of active treatment followed by a seven-day
break). There was a significant increase in airway reactivity
in the group with natural menstrual cycles in the luteal
phase, coincident with the increase in progesterone and
estradiol. In the OC group the hormonal profile was
stable, and so was bronchial reactivity. They concluded
that asthmatic patients receiving the OC had attenuated
cyclical change in airway reactivity as well as reduced diur-
nal peak expiratory flow rate variability, which was associ-
ated with suppression of the normal luteal phase rise in
sex-hormones [58].
How and why can OC reduce PMA
How this beneficial effect is obtained? One possible ex-
planation could be the regulation of the immune system.
An exaggerated Th2-driven response is believed to lead
the inflammatory allergic reaction of asthma. Particularly,
Th2 cytokines induce the production of IgE and mast
cells, activation and recruitment of eosinophils, and air-
way hyperreactivity and mucus secretion [59]. Of major
importance are induced regulatory T cells (iTregs),
which can inhibit or suppress the effector function of T
helper cells and their tolerance to environmental aller-
gens [59–61] thus preventing the induction or reducing
the severity of asthma [59–61].
Sex hormones may directly contribute to the per-
turbed development of iTregs perpetuating the asth-
matic inflammation in an at-risk female population.
Consistent with this possibility, the lower and more
stable levels of circulating hormones in women with
asthma using OC were associated with higher percent-
ages of iTregs when compared with non-OC patients
[59–61].
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These results identify an impact of sex hormones in
the capacity of T cells to polarize towards a regulatory
phenotype and suggest the regulation of peripheral T
cell lineage plasticity as a potential mechanism under-
lying the beneficial effects of OC in women with
asthma [59–61].
Preventive strategies for PMA
Understanding that the menstrual fall of estradiol and
progesterone triggers asthmatic crises in vulnerable
women may suggest new preventive strategies which
are pathophysiologically oriented, such as stabilizing es-
tradiol and progesterone/progestins levels and reducing
the hormone free interval (HFI), when OC is consid-
ered. Prospective controlled studies are needed to test
this working hypothesis.
Menstrual symptoms are complained of as well, al-
though with reduced intensity, during the HFI. The
original interval of seven days has been progressively
reduced to 4 and to 2, with a significant reduction of
menstrual symptoms, or deleted for three or more
months (“extended regimens”, when the woman may
have periods every 91 days). A solid evidence (Harmony I
and II) [62, 63] supports the significant advantages in
terms of menstrual headache and chronic pelvic pain im-
provement by reducing HFI.
Advantages of providing stable hormone levels in place
of monthly hormonal fluctuations
Menstrual bleeding is not biologically necessary in women
taking OC. Rather, for physical and mental good health,
women require appropriate, stable levels of oestrogens,
progesterone and androgens [3, 4].
OC have traditionally been administered with 21 days
of active treatment followed by a seven-day break (a ‘21/
7’ pattern) during which withdrawal bleeding occurs. It
is worth noting that the 7 days HFI, designed in the pio-
neering years of OC, had a psychosocial, not a medical
reason. It was simply needed to reassure women that
they were not pregnant, amenorrhea being for millennia
the first symptom and sign of pregnancy. Today this is
no more the case. Data [64] show a strong cultural
effect: women in high income country tend to have a
very flexible relationship with their periods, the Nether-
land leading the ranking with 85 % asking to postpone/
avoid the cycle, vs 10 % of women in Turkey. Newer for-
mulations are available in which the HFI is reduced or
in some cases eliminated altogether.
There are three major rationales for a shorter HFI:
1. To reduce menstrual symptoms
Shortening HFI reduces genital and systemic
inflammation and symptoms associated with
hormone withdrawal. In a study of nearly 300
women, pelvic pain, headache, breast tenderness,
bloating/swelling and analgesic use were all
significantly more frequent during the seven-day
HFI than in the 21 days of active treatment [65].
OC with a shortened HFI provides markedly
greater suppression of ovarian activity and limits
the extent of exogenous hormonal fluctuations
throughout the cycle, and has been shown to re-
duce or eliminate these symptoms [65].
2. To provide more powerful ovarian suppression and
consequently increase contraceptive efficacy [65].
3. To reduce heavy menstrual bleeding (HMB)
HMB affects around one in three women and has a
significant negative impact on quality of life [66, 67].
The pill with oestradiol valerate and dienogest (E2V/
DNG), administered on a 26/2 regimen, significantly re-
duces the duration and severity of the menstrual bleed-
ing and it is the only one approved for the treatment of
HMB and consequent anemia.
Anemia is a risk factor for asthma
In one study from Ramakrishnan et al., anemic children
resulted 5.75 times more susceptible to asthmatic attacks
when compared with non-anemic children [68].
Moreover, anemia can worsen dyspnea related to
asthma, severely impairing oxygen delivery because the
bulk of oxygen carried in the blood is hemoglobin-
bound [69].
An adequate level of iron has a protective effect on the
respiratory system. A study from Hale et al., proved that
mice fed an iron-supplemented diet had markedly de-
creased allergen-induced airway hyperreactivity, eosino-
phil infiltration, and production of pro-inflammatory
cytokines, compared with control mice on an unsupple-
mented diet that generated mild iron deficiency but not
anemia. In vitro, iron supplementation decreased MC
granule content, IgE-triggered degranulation, and produc-
tion of pro-inflammatory cytokines post-degranulation.
Iron supplementation can decrease the severity of allergic
inflammation in the lung, via multiple mechanisms that
affect MC activity [70].
Evidence supporting the benefits of reducing the HFI
From 7 to 4 days
Shortening of the 7-day HFI (21/7) from 7 to 4 days (24/4):
all of the 24/4 regimens, including EE/DSPR, EE/Noretin-
drone acetate and E2/NOMAC, have shown comparable
or more favourable effects than 21/7 regimens in terms of
efficacy and safety profiles.
This translates into improved menstrual symptoms
control: significant reduction of PMS symptoms [71],
dysmenorrhoea [71], premenstrual dysphoria disorder
(PMDD) [72], and improvements in quality of life [4].
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From 7 to 2 days
The benefits of shortening the HFI may be even greater
when further reducing it from 7 to 2 days. E2V/DNG is
a 26/2-pattern COC that features quadriphasic dosing,
delivering a reducing dose of oestrogen over days 1–26
and an increasing dose of progestogen over days 3–24,
followed by two hormone-free days. E2V/DNG is the
first OC approved for the treatment of HMB due to
endometrial dysfunction. Benefits include:
➢ Contraceptive efficacy [73]
➢ Reduction of HMB, thus reducing anemia that
potentiate asthma with an independent mechanism
[68–70, 74, 75].
Role of the E2V/DNG pill in reducing menstrual symptoms
E2V/DNG reduces the intensity of menstrual symptoms
by offering constant levels of oestradiol around 50 pico-
grams/mL (range 37–62), thus modulating and reducing
the MC degranulation triggered by a more dramatic hor-
monal fall typical of the natural cycle (when oestradiol
moves from 50 to 100 pg/mL after periods, up to 400–
500 pg/mL at ovulation and around 200 pg/mL in the
luteal phase) [4].
Depression associated with HMB
Reducing the blood loss, E2V/DNG decreases iron-
loss anemia, which may be a risk factor for anxiety
[76, 77], poor concentration, attention and memory
[78], fatigue [79].
The effect of E2V/DNG on maintaining iron levels has a
positive effect on the dopaminergic system, which is in-
volved in ameliorating mood, assertiveness, physical and
mental energy, and reducing the risk of depression. More-
over, it can reduce the periodical asthmatic crisis, which
may be so important to cause a post-traumatic stress dis-
order [80], and the need of corticosteroids boluses and
chronic therapy thus reducing the collateral effects such
as weight augmentation [81]
Menstrual migraine and pelvic pain
E2V/DNG has shown a reduction in systemic symptoms
associated with the HFI such as headache [82].
Conclusions
Asthma is one of the most common chronic respiratory
diseases. The prevalence of asthma ranges from 9.1 to
9,7 % in adult women and 5.1 to 5,5 % in men [1, 2].
PMA is usually described as cyclical deterioration of
asthma during the luteal phase and/or during the first
days of menstruation [25, 26], and is reported to be
about 19 % of asthmatic women, while other studies re-
ported the incidence to be as high as 40 % [27].
These menstrual phase findings support the hypothesis
that hormonal status may influence asthma in women,
focusing on the role of sex hormones, and specifically on
the impact of estrogens’ fluctuations at ovulation and
before periods [28].
Women today have many more periods in their lifetime
than their ancestors. Menstrual bleeding is not biologically
necessary in women taking hormonal contraceptives. Fur-
thermore, it may be advantageous for the women to have
more stable levels of hormones throughout the cycle. The
monthly fluctuations in oestrogens, progesterone and an-
drogens are associated with a range of symptoms, both
genital (i.e. vaginal bleeding, heavy menstrual bleeding,
dysmenorrhoea and pelvic pain) and systemic (depression,
fatigue, headache, IBS symptoms, asthma and allergy),
triggered by a local and systemic rise in inflammatory
molecules released by MC when estrogens drop. These
symptoms arise through a complex interaction between
the endocrine and immune systems.
OCs traditionally feature a 7-day HFI, during which
menstruation occurs. Formulations with a shorter HFI
have recently been developed with the aim of offering a
reduction in hormone withdrawal-associated symptoms
together with more powerful ovarian suppression. E2V/
DNG is administered on a 26/2 regimen and has been
shown to offer high contraceptive efficacy together with
a reduction in heavy menstrual bleeding, improvement
in hormone withdrawal-associated symptoms and im-
provement in sexual function. E2V/DNG may, therefore,
be a good alternative to conventional 21/7 COCs for
women with bothersome COC- or menstruation-related
symptoms, as exacerbation of asthma crisis.
Prospective controlled studies are needed to confirm
the working hypothesis, supported by preliminary evi-
dence, that reduction of HFI translates into a significant
reduction of PMA; to evaluate in head to head studies
if a regimen with natural estradiol-valerate/dienogest
with 2 days interval has a different impact on PMA in
comparison to a continuous regimen with EE 30 mcg
and levonorgestrel.
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